Pathway & designation strategy
Pathway selection — 505(b)(1)/(2), BLA, MAA and equivalents — and designation strategy such as Breakthrough, Fast Track, PRIME or Orphan, matched to the strength of the evidence package.
Global regulatory strategy
Sequencing across FDA, EMA, MHRA and other regional authorities so a filing in one region strengthens, rather than complicates, the next.
Health-authority engagement strategy
Meeting strategy, briefing-book positioning and scientific-advice planning built around the questions a reviewer will actually ask.
Lifecycle & post-approval strategy
Label-expansion, post-marketing commitment and lifecycle-management planning built into the regulatory position from the start, not added after approval.